Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies

Inclusion Criteria: * All of the following: Subjects with a cyto- or histopathologically confirmed diagnosis of newly diagnosed: * AML or * biphenotypic acute leukemia with predominantly myeloid features undergoing myeloablative treatment analogous to AML or * refractory anemia with excess of blasts (RAEB) or refractory anemia with excess of blasts in transformation (RAEB-t) with an IPSS score of \>1.5 (appendix 10.8.) and * ECOG performance status (PS) £2 (see appendix 10.2.) and * Written informed consent Exclusion Criteria: One or more of the following: * Contraindication to myeloablative chemotherapy, intravenous lipids, or TPN * Previous or concomitant chronic inflammatory bowel disease, unspecified colitis or pancreatitis * Impaired hepatic or renal function as defined by: * ALAT and/or ASAT \>3 x upper normal limit (UNL) and/or Bilirubin \>3 x UNL unless increase is most likely caused by AML organ infiltration * Serum creatinin \>3 x UNL (after adequate hydration), unless increase is most likely caused by AML organ infiltration * Other concurrent severe and/or uncontrolled medical condition